Johns Hopkins Drug Discovery - Project - Chemotherapy-Induced Neropathy
55
page-template,page-template-full_width,page-template-full_width-php,page,page-id-55,page-child,parent-pageid-19,ajax_fade,page_not_loaded,,qode-theme-ver-7.7,wpb-js-composer js-comp-ver-4.12.1,vc_responsive

Intranasal Insulin

Administration of intranasal insulin represents a promising therapeutic approach for the treatment of cognitive disorders based on several preclinical and clinical reports indicating a role for this hormone in cognitive function.1-3 Intranasal administration can provide rapid delivery of insulin selectively to the brain via bulk flow along olfactory and trigeminal perivascular channels, and via olfactory bulb axonal transport while maintaining peripheral euglycemia. As the Therapeutic Core of the Johns Hopkins NIMH Center for Novel Therapeutics for HIV-Associated Neurocognitive Disorders, JHDD is collaborating with other cores of the center to test the effect of intranasal insulin on cognition in a rodent model of HAND, and to fully characterize the pharmacokinetics of insulin administered via this route. Efforts to delineate the mechanism of insulin efficacy in HAND are also underway with particular attention being paid to the effect of insulin on energy metabolism in key brain regions, as well as a potential effect on viral load. These experiments will inform study design and dose selection for a clinical trial of intranasal insulin administration in HAND patients currently being enrolled by Johns Hopkins collaborators.

 

REFERENCES

  1. Craft, S.; Asthana, S.; Newcomer, J. W.; Wilkinson, C. W.; Matos, I. T.; Baker, L. D.; Cherrier, M.; Lofgreen, C.; Latendresse, S.; Petrova, A.; Plymate, S.; Raskind, M.; Grimwood, K.; Veith, R. C. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch. Gen. Psychiatry 1999, 56, 1135-40.
  2. Mamik, M. K.; Asahchop, E. L.; Chan, W. F.; Zhu, Y.; Branton, W. G.; McKenzie, B. A.; Cohen, E. A.; Power, C. Insulin Treatment Prevents Neuroinflammation and Neuronal Injury with Restored Neurobehavioral Function in Models of HIV/AIDS Neurodegeneration. J. Neurosci. 2016, 36, 10683-10695.
  3. Saylor, D.; Dickens, A. M.; Sacktor, N.; Haughey, N.; Slusher, B.; Pletnikov, M.; Mankowski, J. L.; Brown, A.; Volsky, D. J.; McArthur, J. C. HIV-associated neurocognitive disorder – pathogenesis and prospects for treatment. Nat. Rev. Neurol. 2016, 12, 309.
lowgo_bottom